2Q25 业绩好于市场预期公司公布2Q25 业绩：收入15.3 亿美元，同比+11.9%；核心EPS 0.67 美元，2Q24 为0.62 美元。由于TAVR 增速回暖和二三尖瓣新品快速放量，2季度业绩超出市场预期。发展趋势竞争格局好转+适应症拓展助力TAVR 增速企稳回升。2 季度TAVR（经导管主动脉瓣置换）收入11.3 亿美元，同比+8.9%（剔除汇率影响后，美国和非美市场同比增速均为...
Source Link2Q25 业绩好于市场预期公司公布2Q25 业绩：收入15.3 亿美元，同比+11.9%；核心EPS 0.67 美元，2Q24 为0.62 美元。由于TAVR 增速回暖和二三尖瓣新品快速放量，2季度业绩超出市场预期。发展趋势竞争格局好转+适应症拓展助力TAVR 增速企稳回升。2 季度TAVR（经导管主动脉瓣置换）收入11.3 亿美元，同比+8.9%（剔除汇率影响后，美国和非美市场同比增速均为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.